Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Bio - Europe

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon Oct 23, 2020 1:42pm

421 Views

Post# 31771669

Bio - Europe

Seems like ATE is not presenting, nor are they "on demand."
Leads me to believe they will only be part of the 1-on-1 partnering discussions.
If you find time to snoop around, let me know if you find something different re. Antibe.

Looks like all the big Pharmas are sponsoring.

https://informaconnect.com/bioeurope/agenda/6/

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for May 28, 2024